STAT3 and colorectal carcinoma: As treatment with a TGFBR1-specific inhibitor Galunisertib dramatically suppresses CRC liver metastasis, inhibitors for the IL-11/gp130/STAT3 pathways may also evoke similar anti-metastatic responses [36].